Brenda Finucane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brenda Finucane has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Christa Lese Martin
Department of Clinical Sciences Florida State University College of Medicine, Institute for Pediatric Rare Diseases Tallahassee Florida USA
6 shared publicationsScott M. Myers
Department of Developmental Medicine Geisinger Lewisburg Pennsylvania USA
5 shared publications- David H. Ledbetter
Florida State University
4 shared publications David H. Ledbetter
Department of Clinical Sciences Florida State University College of Medicine, Institute for Pediatric Rare Diseases Tallahassee Florida USA
3 shared publicationsMatthew T. Oetjens
Department of Developmental Medicine Geisinger Lewisburg Pennsylvania USA
3 shared publications- Scott M. Myers
Geisinger
3 shared publications
Latest Publications
- 29 May 2025
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 198 (7) , e33034-75
Apples, Oranges, and Biobanks: Ascertainment Bias in Population‐Based Studies of Neurodevelopmental Psychiatric Disorders
- 29 May 2025
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 198 (7) , e33034-75
Apples, Oranges, and Biobanks: Ascertainment Bias in Population‐Based Studies of Neurodevelopmental Psychiatric Disorders
- Open Access
- 15 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
A genome-first study of sex chromosome aneuploidies provides evidence of Y chromosome dosage effects on autism risk
A female protective effect has long been postulated as the primary explanation for the four-fold increase of autism spectrum disorder (ASD) diagnoses in males versus females. However, genetic and epidemiological investigations of this hypothesis have so far failed to explain the large difference in ASD prevalence between the sexes. To address this knowledge gap, we examined sex chromosome aneuploidy in a large ASD case-control cohort to evaluate the relationship between X and Y chromosome dosage and ASD risk. From these data, we modeled three relationships between sex chromosome dosage and ASD risk: the extra Y effect, the extra X effect, and sex chromosome haploinsufficiency. We found that the extra Y effect increased ASD risk significantly more than the extra X effect. Among females, we observed a large association between 45, X and ASD, confirming sex chromosome haploinsufficiency as a strong ASD risk factor. These results provide a framework for understanding the relationship between X and Y chromosome dosage on ASD, which may inform future research investigating genomic contributors to the observed sex difference.
- 15 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessA genome-first study of sex chromosome aneuploidies provides evidence of Y chromosome dosage effects on autism risk
A female protective effect has long been postulated as the primary explanation for the four-fold increase of autism spectrum disorder (ASD) diagnoses in males versus females. However, genetic and epidemiological investigations of this hypothesis have so far failed to explain the large difference in ASD prevalence between the sexes. To address this knowledge gap, we examined sex chromosome aneuploidy in a large ASD case-control cohort to evaluate the relationship between X and Y chromosome dosage and ASD risk. From these data, we modeled three relationships between sex chromosome dosage and ASD risk: the extra Y effect, the extra X effect, and sex chromosome haploinsufficiency. We found that the extra Y effect increased ASD risk significantly more than the extra X effect. Among females, we observed a large association between 45, X and ASD, confirming sex chromosome haploinsufficiency as a strong ASD risk factor. These results provide a framework for understanding the relationship between X and Y chromosome dosage on ASD, which may inform future research investigating genomic contributors to the observed sex difference.
- 22 April 2023
- Published by Wiley in Autism Research
- Vol. 16 (4) , 678
Letter to the editor
- Open Access
Gathering the Stakeholder’s Perspective: Experiences and Opportunities in Rare Genetic Disease Research
Background: Research participant feedback is rarely collected; therefore, investigators have limited understanding regarding stakeholders’ (affected individuals/caregivers) motivation to participate. Members of the Genes to Mental Health Network (G2MH) surveyed stakeholders affected by copy number variants (CNVs) regarding perceived incentives for study participation, opinions concerning research priorities, and the necessity for future funding. Respondents were also asked about feelings of preparedness, research burden, and satisfaction with research study participation. Methods: Modified validated surveys were used to assess stakeholders´ views across three domains: (1) Research Study Enrollment, Retainment, Withdrawal, and Future Participation; (2) Overall Research Experience, Burden, and Preparedness; (3) Research Priorities and Obstacles. Top box score analyses were performed. Results: A total of 704 stakeholders´ responded from 29 countries representing 55 CNVs. The top reasons for initial participation in the research included reasons related to education and altruism. The top reasons for leaving a research study included treatment risks and side effects. The importance of sharing research findings and laboratory results with stakeholders was underscored by participants. Most stakeholders reported positive research experiences. Conclusions: This study provides important insight into how individuals and families affected with a rare CNV feel toward research participation and their overall experience in rare disease research. There are clear targets for areas of improvement for study teams, although many stakeholders reported positive research experiences. Key findings from this international survey may help advance collaborative research and improve the experience of participants, investigators, and other stakeholders moving forward.
Open AccessGathering the Stakeholder’s Perspective: Experiences and Opportunities in Rare Genetic Disease Research
Background: Research participant feedback is rarely collected; therefore, investigators have limited understanding regarding stakeholders’ (affected individuals/caregivers) motivation to participate. Members of the Genes to Mental Health Network (G2MH) surveyed stakeholders affected by copy number variants (CNVs) regarding perceived incentives for study participation, opinions concerning research priorities, and the necessity for future funding. Respondents were also asked about feelings of preparedness, research burden, and satisfaction with research study participation. Methods: Modified validated surveys were used to assess stakeholders´ views across three domains: (1) Research Study Enrollment, Retainment, Withdrawal, and Future Participation; (2) Overall Research Experience, Burden, and Preparedness; (3) Research Priorities and Obstacles. Top box score analyses were performed. Results: A total of 704 stakeholders´ responded from 29 countries representing 55 CNVs. The top reasons for initial participation in the research included reasons related to education and altruism. The top reasons for leaving a research study included treatment risks and side effects. The importance of sharing research findings and laboratory results with stakeholders was underscored by participants. Most stakeholders reported positive research experiences. Conclusions: This study provides important insight into how individuals and families affected with a rare CNV feel toward research participation and their overall experience in rare disease research. There are clear targets for areas of improvement for study teams, although many stakeholders reported positive research experiences. Key findings from this international survey may help advance collaborative research and improve the experience of participants, investigators, and other stakeholders moving forward.
- Open Access
Frequency of FLCN Loss of Function Variants and Birt-Hogg-Dubé-Associated Phenotypes in a Healthcare System Population
Purpose: Current penetrance estimates of Birt-Hogg-Dubé (BHD)-associated cutaneous, pulmonary, and renal manifestations are based on clinically ascertained families. In a healthcare system population, we used a genetics-first approach to estimate the prevalence of pathogenic/likely pathogenic (P/LP) variants in the FLCN gene, which cause BHD, and the penetrance of BHD-related phenotypes. Methods: Exomes from 135,990 patient-participants in Geisinger’s MyCode® cohort were assessed for P/LP FLCN variants. BHD-related phenotypes were evaluated from electronic health records. Association between FLCN P/LP variants and BHD-related phenotypes were assessed by Firth’s logistic regression. Results: P/LP FLCN variants were identified in 35 (1 in 3,234) individuals, 68.6% of whom had BHD-related phenotype(s) including: cystic lung disease (65.7%); pneumothoraces (17.1%); cutaneous manifestations (8.6%); and renal cancer (2.9%). Only four (11.4%) were clinically diagnosed with BHD. Conclusion: In this healthcare population, the frequency of P/LP FLCN variants is 60 times higher than the previously reported prevalence. Although most variant-positive individuals had BHD-related phenotypes in the EHR, a minority were clinically diagnosed with BHD, likely because cutaneous manifestations, pneumothoraces, and renal cancer were observed at lower frequencies than clinical cohorts. Improved clinical recognition of cystic lung disease and education concerning its association with FLCN variants could prompt evaluation for BHD.
Open AccessFrequency of FLCN Loss of Function Variants and Birt-Hogg-Dubé-Associated Phenotypes in a Healthcare System Population
Purpose: Current penetrance estimates of Birt-Hogg-Dubé (BHD)-associated cutaneous, pulmonary, and renal manifestations are based on clinically ascertained families. In a healthcare system population, we used a genetics-first approach to estimate the prevalence of pathogenic/likely pathogenic (P/LP) variants in the FLCN gene, which cause BHD, and the penetrance of BHD-related phenotypes. Methods: Exomes from 135,990 patient-participants in Geisinger’s MyCode® cohort were assessed for P/LP FLCN variants. BHD-related phenotypes were evaluated from electronic health records. Association between FLCN P/LP variants and BHD-related phenotypes were assessed by Firth’s logistic regression. Results: P/LP FLCN variants were identified in 35 (1 in 3,234) individuals, 68.6% of whom had BHD-related phenotype(s) including: cystic lung disease (65.7%); pneumothoraces (17.1%); cutaneous manifestations (8.6%); and renal cancer (2.9%). Only four (11.4%) were clinically diagnosed with BHD. Conclusion: In this healthcare population, the frequency of P/LP FLCN variants is 60 times higher than the previously reported prevalence. Although most variant-positive individuals had BHD-related phenotypes in the EHR, a minority were clinically diagnosed with BHD, likely because cutaneous manifestations, pneumothoraces, and renal cancer were observed at lower frequencies than clinical cohorts. Improved clinical recognition of cystic lung disease and education concerning its association with FLCN variants could prompt evaluation for BHD.
- Open Access
- 18 November 2021
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (3) , 703-711
Medical manifestations and health care utilization among adult MyCode participants with neurodevelopmental psychiatric copy number variants
- 18 November 2021
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (3) , 703-711
Open AccessMedical manifestations and health care utilization among adult MyCode participants with neurodevelopmental psychiatric copy number variants
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e38-E38
DELETERIOUS “SHIFT” IN FUNCTIONAL PERFORMANCE EXPLAINS CLINICAL VARIABILITY IN RARE GENETIC NEURODEVELOPMENTAL PSYCHIATRIC DISORDERS
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e38-E38
DELETERIOUS “SHIFT” IN FUNCTIONAL PERFORMANCE EXPLAINS CLINICAL VARIABILITY IN RARE GENETIC NEURODEVELOPMENTAL PSYCHIATRIC DISORDERS
- Open Access
- 1 June 2021
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 68, 1-8
Diagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation
- 1 June 2021
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 68, 1-8
Open AccessDiagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S36-S37
Identifying loss of function FLCN variants and Birt-Hogg-Dube-associated phenotypes in a large, healthcare-based cohort
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S36-S37
Identifying loss of function FLCN variants and Birt-Hogg-Dube-associated phenotypes in a large, healthcare-based cohort
- 5 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (6) , 1922-1924
Birt‐Hogg‐Dubé symptoms in Smith‐Magenis syndrome include pediatric‐onset pneumothorax
- 5 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (6) , 1922-1924
Birt‐Hogg‐Dubé symptoms in Smith‐Magenis syndrome include pediatric‐onset pneumothorax